Champions Oncology, Inc. (CSBR) stock
CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.44−0.15 (-3.30%)
Close on Nov 18, 2026Market cap $61.80MP/E –Yield –
Champions Oncology price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Champions Oncology's price to sales ratio was 1.1× on Nov 11, 2026, against 1.6× a year earlier. Over the last 5 years it ranged from 1.0× to 2.8×, with a median of 1.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.1× | −0.5 |
| 2025 | Dec 31, 2025 | 1.6× | −0.5 |
| 2024 | Dec 31, 2024 | 2.2× | +0.7 |
| 2023 | Dec 29, 2023 | 1.5× | +0.4 |
| 2022 | Dec 30, 2022 | 1.1× | −1.4 |
| 2021 | Dec 31, 2021 | 2.5× | −1.3 |
| 2020 | Dec 31, 2020 | 3.9× | +0.5 |
| 2019 | Dec 31, 2019 | 3.4× | −0.5 |
| 2018 | Dec 31, 2018 | 3.9× | +1.5 |
| 2017 | Dec 29, 2017 | 2.4× | +0.4 |
| 2016 | Dec 30, 2016 | 2.1× | −0.8 |
| 2015 | Dec 31, 2015 | 2.9× | −0.5 |
| 2014 | Dec 31, 2014 | 3.4× | −0.9 |
| 2013 | Dec 31, 2013 | 4.2× | +2.8 |
| 2012 | Dec 31, 2012 | 1.4× | −1.9 |
| 2011 | Dec 30, 2011 | 3.3× | – |
See a number that looks wrong?